IP Verse

Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Tigit Inhibitors - EP3021869

The patent EP3021869 was granted to F Hoffmann LA Roche on Jul 15, 2020. The application was originally filed on Jul 16, 2014 under application number EP14750063A. The patent is currently recorded with a legal status of "Revoked".

EP3021869

F HOFFMANN LA ROCHE
Application Number
EP14750063A
Filing Date
Jul 16, 2014
Status
Revoked
Mar 7, 2025
Grant Date
Jul 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARES TRADINGApr 15, 2021MERCK SERONOADMISSIBLE
JAMES POOLEApr 15, 2021CARPMAELS & RANSFORDADMISSIBLE
DR H ULRICH DORRIESApr 14, 2021DORRIESADMISSIBLE
DR H ULRICH DORRIESApr 14, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2006121168
INTERNATIONAL-SEARCH-REPORTWO2009126688
INTERNATIONAL-SEARCH-REPORTWO2010077634
INTERNATIONAL-SEARCH-REPORTWO2011066342
OPPOSITIONEP2279412
OPPOSITIONUS2007054360
OPPOSITIONUS7943743
OPPOSITIONWO2006121168
OPPOSITIONWO2006124667
OPPOSITIONWO2009126688
OPPOSITIONWO2010077634
OPPOSITIONWO2011066342

Non-Patent Literature (NPL) Citations (42) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Jane Grogan ET AL, "TIGIT inhibits CD8+ T cell effector function during chronic viral infection and cancer (TUM7P.933) | The Journal of Immunology", THE JOURNAL OF IMMUNOLOGY, US, (20140101), vol. 192, no. Suppl. 1, ISSN 0022-1767, page 203.15, XP055396554-
EXAMINATION- Laetitia Comps-Agrar ET AL, "TIGIT mediated T cell exhaustion in cancer is dependent on TIGIT/CD226 interaction (TUM2P.907)", The Journal of Immunology, (20140501), vol. 192, no. S1, XP055254520-
INTERNATIONAL-SEARCH-REPORT- INOZUME T ET AL, "Development of a novel immunotherapy for melanoma which inhibits interaction between CD155 on melanoma cells and TIGIT on activated CTL", JOURNAL OF INVESTIGATIVE DERMATOLOGY, & INTERNATIONAL INVESTIGATIVE DERMATOLOGY MEETING; EDINBURGH, UK; MAY 08 -11, 2013, (201305), vol. 133, no. Suppl. 1, page S3, XP002731507 [I] 1-11,42-105,109-114 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- CHRISTOPHER J CHAN ET AL, "Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer", CURRENT OPINION IN IMMUNOLOGY, (20120401), vol. 24, no. 2, doi:10.1016/j.coi.2012.01.009, ISSN 0952-7915, pages 246 - 251, XP055147483 [A] 1-11,42-105,109-120,127-166 * the whole document *
INTERNATIONAL-SEARCH-REPORT- SHAWN D BLACKBURN ET AL, "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection", NATURE IMMUNOLOGY, (20081130), vol. 10, no. 1, doi:10.1038/ni.1679, ISSN 1529-2908, pages 29 - 37, XP055047746 [I] 1-11,42-105,109-120,127-166 * whole document, especially the Abstract and Figure 7 *
INTERNATIONAL-SEARCH-REPORT- P. YU ET AL, "Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120417), vol. 109, no. 16, doi:10.1073/pnas.1203479109, ISSN 0027-8424, pages 6187 - 6192, XP055147800 [I] 1-11,42-105,109-120,127-166 * whole document, especially the Abstract and Figure 1 *
INTERNATIONAL-SEARCH-REPORT- NICOLE JOLLER ET AL, "Immune checkpoints in central nervous system autoimmunity", IMMUNOLOGICAL REVIEWS, (20120101), vol. 248, pages 122 - 139, XP055145273 [A] 1-11,42-105,109-120,127-166 * the whole document *
INTERNATIONAL-SEARCH-REPORT- Q. ZHOU ET AL, "Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia", BLOOD, (20110308), vol. 117, no. 17, doi:10.1182/blood-2010-10-310425, ISSN 0006-4971, pages 4501 - 4510, XP055147794 [I] 1-11,42-105,109-120,127-166 * whole document, especially the Abstract and Figure 6B *
OPPOSITION- Anonymous, "2013 International Investigative Dermatology Meeting", J INVEST DERMATOL, Edinburg, Scotland, United Kingdom, Edinburg, Scotland, United Kingdom, (20130508), XP055963088-
OPPOSITION- Anonymous, "Adaptive Immunity abstracts of the 2013 International Investigative Dermatology Meeting", J INVEST DERMATOL, (20130511), J INVEST DERMATOL, URL: www.jidonline.org, (20220921), XP055963091-
OPPOSITION- Asher Mullard D., "New Checkpoint inhibitors ride the immunotherapy tsunami", Nature Reviews Drug Discovery, (20130701), vol. 12, XP055963059-
OPPOSITION- HAMID, O. et al., Expert Opin. Biol. Ther., (20130000), vol. 13, no. 6, pages 847 - 61-
OPPOSITION- Jane Grogan, Robert Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Dan Eaton and Summer Park, "TIGIT inhibits CD8+ T cell effector function during chronic viral infection and cancer (TUM7P.933) | The Journal of Immunology", The Journal of Immunology, Williams & Wilkins Co., US, US , (20140101), vol. 192, no. Suppl. 1, ISSN 0022-1767, page 203.15, XP055396554-
OPPOSITION- JOLLER, N. et al., Immunol. Rev., (20120000), vol. 248, pages 122 - 139-
OPPOSITION- Laetitia Comps-Agrar, Robert Johnston1 Jason Hackney, Xin Yu, Yagai Yang, Mahrukh Huseni, Dan Eaton1 And Jane Grogan, "TIGIT mediated T cell exhaustion in cancer is dependent on TIGIT/CD226 interaction (TUM2P.907)", The Journal of Immunology, (20140501), vol. 192, no. S1, XP055254520-
OPPOSITION- Selby Mark, Et Al., "Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1in preclinical models", Journal of Clinical Oncology, (20130101), vol. 31, no. 15, XP055963056-
OPPOSITION- T Inozume, J Furuta, K Harada, T Yaguchi, Y Kawakami and S Shimada, "Development of a novel immunotherapy for melanoma which inhibits interaction between CD155 on melanoma cells and TIGIT on activated CTL", Journal of Investigative Dermatology, Elsevier, NL, NL , (20130501), vol. 133, no. Suppl. 1, ISSN 0022-202X, page S3, XP002731507-
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages n/a - n/a, XP055157252
OPPOSITION- Steven D. Levin, David W. Taft, Cameron S. Brandt, Christoph Bucher, Edward D. Howard, Eric M. Chadwick, Janet Johnston, Angela Hammond, Kristen Bontadelli, Daniel Ardourel, Luann Hebb, Anitra Wolf, Thomas R. Bukowski, Mark W. Rixon, Joseph L. Kuijper, Craig D. Ostrander, James W. West, Janine Bilsborough, Brian Fox, Zeren Gao, Wenfeng Xu, Fred Ramsdell, Bruce R. Blazar, Katherine E. Lewis, "Vstm3 is a member of the CD28 family and an important modulator of T-cell function", European Journal of Immunology, Wiley-VCH, (20110418), vol. 41, no. 4, doi:10.1002/eji.201041136, ISSN 00142980, pages 902 - 915, XP055215809
OPPOSITION- A. Hutloff, "T-cell costimulation ; Basic mechanisms and new aspects ; T-Zell-Kostimulation ; Grundlegende Mechanismen und neue Entwicklungen", Zeitschrift für Rheumatologie, Steinkopff-Verlag, Da, Da , (20110821), vol. 70, no. 7, doi:10.1007/s00393-011-0862-y, ISSN 1435-1250, pages 588 - 591, XP019948938
OPPOSITION- Christopher J Chan, Daniel M Andrews, Mark J Smyth, "Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer", Current Opinion in Immunology, Elsevier Current Trends, (20120401), vol. 24, no. 2, doi:10.1016/j.coi.2012.01.009, ISSN 09527915, pages 246 - 251, XP055147483
OPPOSITION- Inozume Takashi; Furuta Junpei; Harada Kazutoshi; Shimada Shinji, "CD155 is highly expressed by melanoma tissues and it suppresses the activation of melanoma specific CTLs via interaction with TIGIT", Journal of Dermatological Science, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19000101), vol. 69, no. 2, doi:10.1016/j.jdermsci.2012.11.509, ISSN 0923-1811, XP028971655
OPPOSITION- S A Quezada, K S Peggs, "Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer", British Journal of Cancer, Nature Publishing Group UK, London, London, (20130430), vol. 108, no. 8, doi:10.1038/bjc.2013.117, ISSN 0007-0920, pages 1560 - 1565, XP055344904
OPPOSITION- Yu X; Harden K; Gonzalez L C; Francesco M; Chiang E; Irving B; Tom I; Ivelja S; Refino C J; Clark H; Eaton D; Grogan J L, "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells", Nature Immulogy, Nature Publishing Group US, New York, New York , (20090101), vol. 10, no. 1, doi:10.1038/ni.1674, ISSN 1529-2908, pages 48 - 57, XP008108747
OPPOSITION- Shawn D Blackburn, Shin Haina, Haining W Nicholas, Zou Tao, Workman Creg J, Polley Antonio, Betts Michael R, Freeman Gordon J, Vignali Dario A A, Wherry E John, "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection", Nature Immunology, Nature America Inc., (20090101), vol. 10, no. 1, doi:10.1038/ni.1679, ISSN 15292908, pages 29 - 37, XP055047746
OPPOSITION- Jedd D. Wolchok, Harriet Kluger, Margaret K. Callahan, Michael A. Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil H. Segal, Charlotte E. Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie A. Kronenberg, Blessing U. Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E. Horak, Quan Hong, Alan J. Korman, Jon M. Wigginton, Ashok Gupta, Mario Sznol, "Nivolumab plus Ipilimumab in Advanced Melanoma", New England Journal of Medicine, New England Journal of Medicine, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1302369, ISSN 00284793, pages 122 - 133, XP055182024
OPPOSITION- N. Stanietsky, H. Simic, J. Arapovic, A. Toporik, O. Levy, A. Novik, Z. Levine, M. Beiman, L. Dassa, H. Achdout, N. Stern-Ginossar, P. Tsukerman, S. Jonjic, O. Mandelboim, "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20091020), vol. 106, no. 42, doi:10.1073/pnas.0903474106, ISSN 00278424, pages 17858 - 17863, XP055215810
OPPOSITION- M. A. Curran, W. Montalvo, H. Yagita, J. P. Allison, "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100302), vol. 107, no. 9, doi:10.1073/pnas.0915174107, ISSN 00278424, pages 4275 - 4280, XP055067204
OPPOSITION- J. Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, A. Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant, L. J. Old, K. Odunsi, "Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100427), vol. 107, no. 17, doi:10.1073/pnas.1003345107, ISSN 00278424, pages 7875 - 7880, XP055147797
OPPOSITION- H.-T. Jin, A. C. Anderson, W. G. Tan, E. E. West, S.-J. Ha, K. Araki, G. J. Freeman, V. K. Kuchroo, R. Ahmed, "Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100817), vol. 107, no. 33, doi:10.1073/pnas.1009731107, ISSN 0027-8424, pages 14733 - 14738, XP055254340
OPPOSITION- P. Yu, J. C. Steel, M. Zhang, J. C. Morris, R. Waitz, M. Fasso, J. P. Allison, T. A. Waldmann, "Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20120417), vol. 109, no. 16, doi:10.1073/pnas.1203479109, ISSN 00278424, pages 6187 - 6192, XP055147800
OPPOSITION- DURAISWAMY JAIKUMAR ET AL, "Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors", Cancer research, American Association for Cancer Research, US, US , (20130601), vol. 73, no. 12, doi:10.1158/0008-5472.CAN-12-4100, ISSN 0008-5472, pages 3591 - 3603, XP002775668
OPPOSITION- D. S. Chen, B. A. Irving, F. S. Hodi, "Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1", Clinical Cancer Research, Association for Cancer Research, (20121215), vol. 18, no. 24, doi:10.1158/1078-0432.CCR-12-1362, ISSN 10780432, pages 6580 - 6587, XP055124329
OPPOSITION- Jin Hyung-Seung, Ko Minkyung, Choi Da-Som, Kim June Hyuck, Lee Dong-Hee, Kang Seong-Ho, Kim Inki, Lee Hee Jin, Choi Eun Kyung, Kim Kyu-Pyo, Yoo Changhoon, Park Yoon, "CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy", Cancer immunology research, doi:10.1158/2326-6066.CIR-19-0877, (20200701), pages 912 - 925, Cancer immunology research, (20220920), XP055963012
OPPOSITION- Q. Zhou, M. E. Munger, R. G. Veenstra, B. J. Weigel, M. Hirashima, D. H. Munn, W. J. Murphy, M. Azuma, A. C. Anderson, V. K. Kuchroo, B. R. Blazar, "Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia", Blood, (20110428), vol. 117, no. 17, doi:10.1182/blood-2010-10-310425, ISSN 00064971, pages 4501 - 4510, XP055147794
OPPOSITION- Andrew M. Intlekofer, Craig B. Thompson, "At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy", Journal of Leukocyte Biology, John Wiley & Sons Ltd., GB, GB , (20130701), vol. 94, no. 1, doi:10.1189/jlb.1212621, ISSN 0741-5400, pages 25 - 39, XP055515949
OPPOSITION- M. K. Callahan, J. D. Wolchok, "At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy", Journal of Leukocyte Biology, John Wiley & Sons Ltd., GB, GB , (20130701), vol. 94, no. 1, doi:10.1189/jlb.1212631, ISSN 0741-5400, pages 41 - 53, XP055223891
OPPOSITION- Nobuhiro Nakamoto, Hyosun Cho, Abraham Shaked, Kim Olthoff, Mary E. Valiga, Mary Kaminski, Emma Gostick, David A. Price, Gordon J. Freeman, E. John Wherry, Kyong-Mi Chang, "Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade", PLoS Pathogens, Public Library of Science, (20090201), vol. 5, no. 2, doi:10.1371/journal.ppat.1000313, ISSN 15537366, pages e1000313 - e1000313, XP055050049
OPPOSITION- MALYGUINE AM et al., "ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials", Cells, (20120510), vol. 1, no. 2, doi:10.3390/cells1020111, pages 111 - 126, XP055235246
OPPOSITION- Yeo Jinah, Ko Minkyung, Lee Dong-Hee, Park Yoon, Jin Hyung-Seung, "TIGIT/CD226 Axis Regulates Anti-Tumor Immunity", Pharmaceuticals, M D P I AG, CH, CH , (20210228), vol. 14, no. 3, doi:10.3390/ph14030200, ISSN 1424-8247, page 200, XP055963005
OPPOSITION- N. Joller, J. P. Hafler, B. Brynedal, N. Kassam, S. Spoerl, S. D. Levin, A. H. Sharpe, V. K. Kuchroo, "Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions", The Journal of Immunology, Williams & Wilkins Co., US, US , (20110201), vol. 186, no. 3, doi:10.4049/jimmunol.1003081, ISSN 0022-1767, pages 1338 - 1342, XP055319470
OPPOSITION- E. Lozano, M. Dominguez-Villar, V. Kuchroo, D. A. Hafler, "The TIGIT/CD226 Axis Regulates Human T Cell Function", The Journal of Immunology, American Association of Immunologists, (20120415), vol. 188, no. 8, doi:10.4049/jimmunol.1103627, ISSN 00221767, pages 3869 - 3875, XP055147473

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents